DOTA Zoledronate

Names

[ CAS No. ]:
1908409-18-6

[ Name ]:
DOTA Zoledronate

[Synonym ]:
2,2',2''-{10-[2-({2-[1-(2-Hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl}amino)-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl}triacetic acid
1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[1-(2-hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl]amino]-2-oxoethyl]-

Biological Activity

[Description]:

DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[In Vitro]

DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology[1].

[References]

[1]. The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent.

Chemical & Physical Properties

[ Density]:
1.7±0.1 g/cm3

[ Molecular Formula ]:
C₂₃H₄₁N₇O₁₄P₂

[ Molecular Weight ]:
701.56

[ Exact Mass ]:
701.218689

[ LogP ]:
-3.89

[ Index of Refraction ]:
1.670

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.